Diabetes (Type 2)

About Diabetes (Type 2) Clinical Trials (Click to Open)

Join Clinical Trials for Diabetes Type 2

General Purpose:

Clinical Trials for Diabetes Type 2Living with Type 2 Diabetes results in a constant struggle to manage blood glucose levels. As a result, clinical research is attempting to find new and improved ways to live well with this chronic disease.

Given the necessity of lifestyle changes upon diagnosis, there are many clinical trials attempting to find the most effective behavioral interventions. Interventional trials of this nature will evaluate different behavioral programs related to standard diabetes counseling.

They will assess glycemic control and weight in participants to evaluate the programs. Other trials may evaluate the benefit of pharmaceutical interventions, potentially in conjunction with, or in comparison to, behavioral intervention.

In severely obese patients, clinical trials may perform laparoscopic adjustable gastric band surgery or gastric bypass surgery, to potentially improve metabolic control and treat type 2 diabetes.

These surgeries can provide life-changing results by improving insulin action beyond that of weight loss alone. Given the dire health threat presented by type 2 diabetes in extremely obese individuals, participation in interventional clinical trials can be incredibly beneficial to the future of your health.

As the main goal of this clinical research is to improve the quality of life of those living with diabetes, there are also trials dedicated to improving/facilitating blood sugar monitoring. Other studies are attempting to decipher risk factors for developing type 2 diabetes. These may include genetic and behavioral risk factors.

What will Clinical Trials for Diabetes Type 2 be like?

Before joining a clinical trial, researchers will first assess your eligibility. You will go through a screening phase to ensure that you are an appropriate participant for the aims of the trial.

The goal of these trials is to improve the quality of life of those with Type 2 Diabetes, so Clinical Trials for Diabetes Type 2inclusion criteria are intended to provide this benefit and avoid wasting your time. They are also put in place to avoid any risk of a detrimental interaction between a behavioral or pharmaceutical intervention and an existing condition or medication.

The researchers will therefore ask you to provide a very detailed medical history. Preventative trials will first require participants to undergo in depth screening, including serum glucose and other fasting blood tests. Interventional trials will assess your diagnoses to determine if you are a good candidate for surgical intervention, behavioral, pharmaceutical, etc.

Typical Trial Protocol:

If the main interventional method being tested is a new pharmaceutical, you will be randomly assigned to a group that either receives a varying dose of the treatment or a placebo.

Clinical Trials for Diabetes Type 2If a surgical procedure is part of the treatment, participants will be randomly assigned to a group receiving an interventional surgery, such as gastric band or gastric bypass, in comparison to groups that receive medical and weight management.

They will then receive follow-up assessments of glycemic index, metabolic factors, cardiovascular risk, and quality of life at specified time points after the treatment.

To evaluate this intervention, participants will be asked to visit for follow up physical examinations, blood tests, and urine collection. While participating in these interventional studies, you will receive care and your glucose monitoring, though you may be unable to participate in other studies to avoid detrimental interactions between trial treatments.

Studies conducted to evaluate the clinical utility of risk assessment measures will randomly assign eligible individuals to different risk assessment groups, which may include genetic testing.

Given the impact of behavior on type 2 diabetes, participants will undergo relevant baseline assessments, such as BMI, waist circumference, fasting plasma glucose and insulin.

After receiving counseling about their individual risk, they will return for follow up assessments to determine the effect that this risk information plays on a person’s perception of risk. This will be analyzed through the assessment of resulting behavioral changes made to diet and exercise.

All clinical trials will attempt to provide you personal benefit that improves your quality of life, while also using information provided by your trial experience for the betterment of all diabetic individuals.

Suggested Search Terms:

Type 2 Diabetes and Obesity, Type 2 Diabetes and Blood Glucose Management, Weight loss Programs for Type 2 Diabetes, Type 2 Diabetes Prevention, Risk Assessment for Type 2 Diabetes

Current Search Term Used: “Diabetes Type 2″



A Dose Finding Study to Assess the Effect of LIK066 Compared to Placebo or Empagliflozin in Patients With Type 2 Diabetes Mellitus and Heart Failure


Condition:   Diabetes Type 2 With Heart Failure
Interventions:   Drug: LIK066;   Drug: Placebo;   Drug: Empagliflozin
Sponsor:   Novartis Pharmaceuticals
Not yet recruiting - verified May 2017


Person-centred Interactive Self-management Support in Primary Healthcare for People With Type 2 Diabetes


Condition:   Diabetes Type 2
Interventions:   Behavioral: Intervention arm: Person-centred interactive self-management support;   Other: Control arm;   Other: External comparison group
Sponsors:   Umeå University;   The Swedish Diabetes Foundation;   The County Council of Västerbotten
Recruiting - verified May 2017


Usage of Dapagliflozin in the Management of Type-2 Diabetes Mellitus: A Real World Evidence Study in Indian Patients


Condition:   Type 2 Diabetes
Intervention:  
Sponsor:   AstraZeneca
Recruiting - verified May 2017


The Application of the E-health Education on Shared Care Program for Patients With Type 2 Diabetes


Condition:   Type 2 Diabetes Mellitus
Interventions:   Behavioral: E-health Education;   Other: Routine care
Sponsor:   Li-Li Chen
Recruiting - verified February 2017


Economic Outcomes of EQW (Exenatide Once Weekly) vs. IG (Insulin Glargine) in T2D Patients Who Are New to Injectable Therapy


Condition:   Diabetes Mellitus Type 2
Intervention:  
Sponsors:   AstraZeneca;   Truven health
Completed - verified January 2017


Mineralocorticoid Receptor Antagonists in Type 2 Diabetes


Condition:   Diabetes Type 2
Interventions:   Drug: Eplerenone;   Drug: Placebo
Sponsor:   Herlev Hospital
Active, not recruiting - verified May 2017


Defining the Physiological Mechanisms of Risk Genes for Hyperglycaemia, Insulin Resistance and Type 2 Diabetes


Condition:   Type 2 Diabetes
Interventions:   Other: 4 Hour Frequently Sampled Oral Glucose Tolerance Test;   Other: Isoglycaemic Clamp
Sponsors:   University of Oxford;   University of Exeter;   Medical Research Council
Recruiting - verified June 2016


Impact of Rheumatoid Arthritis on the Course of Type 2 Diabetes During a Longitudinal Follow-up of 5 Years


Condition:   Type 2 Diabetes
Intervention:  
Sponsors:   Assistance Publique - Hôpitaux de Paris;   Recherche Clinique Paris Descartes Necker Cochin Sainte Anne
Recruiting - verified June 2016


Effect of Periodontal Therapy in the Systemic Status of Individuals With Chronic Periodontitis and Diabetes Type 2


Conditions:   Chronic Periodontitis;   Diabetes Type 2
Interventions:   Device: Mechanical periodontal therapy;   Procedure: nonsurgical periodontal therapy
Sponsors:   University of Brasilia;   Catholic University of Brasília;   Brasilia University Hospital
Active, not recruiting - verified May 2017


Effects of Prebiotics on GLP-1 in Type 2 Diabetes


Condition:   Diabetes Type 2
Interventions:   Dietary Supplement: Prebiotic fibers: oligofructose and inulin;   Dietary Supplement: Maltodextrin
Sponsors:   Oslo University Hospital;   Norwegian Diabetes Association;   Norwegian Extra Foundation for Health and Rehabilitation
Recruiting - verified April 2017


Phase II Safety and Efficacy Study of Oral ORMD-0801 in Patients With Type 2 Diabetes Mellitus


Condition:   Diabetes Type 2
Interventions:   Drug: ORMD-0801;   Drug: Placebo Comparator
Sponsors:   Oramed, Ltd.;   Integrium
Completed - verified December 2016


Evaluation of the Effect of Pulsatile Cuts Stendo3 on Vascular Function Patients With Diabetes Type 2


Condition:   Type 2 Diabetes
Intervention:   Device: Combination pulsatile Stendo3
Sponsors:   University Hospital, Clermont-Ferrand;   STENDO, 17 rue du port 27400 LOUVIERS
Recruiting - verified July 2016


DISCOVERing Treatment Reality of Type 2 Diabetes in Real World Settings


Condition:   Type 2 Diabetes Mellitus
Intervention:  
Sponsor:   AstraZeneca
Active, not recruiting - verified March 2017


DISCOVERing Treatment Reality of Type 2 Diabetes in Real World Setting in Japan


Condition:   Type 2 Diabetes Mellitus
Intervention:  
Sponsors:   AstraZeneca;   Ono Pharmaceutical Co. Ltd
Active, not recruiting - verified April 2017


Study of Chiglitazar Compare With Placebo in Type 2 Diabetes Patients


Condition:   Type 2 Diabetes
Interventions:   Drug: Chiglitazar;   Drug: Placebo
Sponsor:   Chipscreen Biosciences, Ltd.
Active, not recruiting - verified February 2017


Diet and Exercise Intervention in Type 2 Diabetes


Condition:   Type 2 Diabetes
Interventions:   Behavioral: Optimum Lifestyle Intervention;   Behavioral: Standard Care
Sponsors:   Washington University School of Medicine;   National Dairy Council;   American Egg Board
Completed - verified April 2017


Provider-Initiated Regular Remote Interventions for Optimal Type 2 Diabetes Care


Condition:   Type 2 Diabetes
Interventions:   Other: Remote, personalized type 2 diabetes care.;   Other: Usual Endocrine care.
Sponsor:   University of Michigan
Active, not recruiting - verified April 2017


Postpartum Screening of Type 2 Diabetes


Condition:   Type 2 Diabetes
Intervention:   Procedure: oral glucose tolerance test 2 days post-partum
Sponsors:   Université de Sherbrooke;   The Lawson Foundation
Active, not recruiting - verified December 2016


Early add-on Vildagliptin in Patients With Type 2 Diabetes Inadequately Controlled by Metformin


Condition:   Type-2 Diabetes Mellitus
Interventions:   Drug: LAF237 (vildagliptin);   Drug: Metformin
Sponsor:   Novartis Pharmaceuticals
Completed - verified April 2017


Early Intermittent Intensive Insulin Therapy as an Effective Treatment of Type 2 Diabetes (RESET-IT Pilot Study)


Condition:   Type 2 Diabetes
Interventions:   Drug: Intermittent insulin therapy;   Drug: Continuous metformin
Sponsors:   Mount Sinai Hospital, Canada;   Canadian Institutes of Health Research (CIHR)
Active, not recruiting - verified March 2017


Safety and Efficacy of Vildagliptin Versus NPH Insulin add-on to Glimepiride in Type 2 Diabetes Mellitus Patients.


Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: LAF237;   Drug: Protaphane
Sponsor:   Novartis Pharmaceuticals
Completed - verified November 2016


Exercise Study on Cardiac Function in Patients With Diabetes Mellitus Type 2 and Diastolic Dysfunction


Condition:   Diabetes Type 2
Intervention:   Other: Exercise
Sponsor:   Norwegian University of Science and Technology
Completed - verified April 2017


Safety and Efficacy Study of EndoBarrier in Subjects With Type II Diabetes and Obesity


Condition:   Type II Diabetes
Interventions:   Device: EndoBarrier;   Behavioral: Diet + Lifestyle Counseling
Sponsor:   GI Dynamics
Completed - verified August 2016


Study for Pre-Surgical Weight Loss in Type II Diabetes Patients


Condition:   Type 2 Diabetes
Intervention:   Device: GI Sleeve
Sponsor:   GI Dynamics
Completed - verified March 2016


Time Course of the Antiproteinuric and Blood Pressure Lowering Effects After Initiation of Renin Inhibition With Aliskiren in Type 2 Diabetes


Condition:   Diabetes Type 2
Intervention:   Drug: Aliskiren
Sponsor:   Novartis
Completed - verified September 2016

Refine Your Search Advanced Search